-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Veru Names Joel Batten Exec VP, Head Of Its US Infectious Disease Franchise
Veru Names Joel Batten Exec VP, Head Of Its US Infectious Disease Franchise
Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022.
Most recently Mr. Batten has been the Head of the Respiratory Syncytial Virus (RSV) Franchise at Sobi North America where he was responsible for the Synagis business with gross revenue of approximately $600M and a team of over 160 employees. Mr. Batten led sales and marketing for the RSV Franchise as well as strategy for market access, distribution and patient access services. Prior to Sobi, he spent approximately 20 years in a number of positions of increasing responsibility at AstraZeneca / MedImmune and Sanofi Aventis in various infectious disease franchises including commercial infrastructure build-out, product launch, sales management, marketing, public health sales, and government affairs.
"Joel is an accomplished commercial leader with extensive knowledge in viral infectious disease product commercialization," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. "We are excited to have Joel join Veru at such a critical juncture in our Company's history as we build on the momentum of our positive Phase 3 sabizabulin for COVID-19 trial, our planned EUA submission, and the transition to delivering sabizabulin, if EUA is granted, to hospitalized COVID-19 patients at high risk for ARDS. Joel will be the head of our newly formed U.S. Infectious Disease Franchise and will be responsible for developing and leading all aspects of our U.S. go-to-market strategy for sabizabulin for COVID, if authorized, as well as planned future indications for other viral and ARDS-related and inflammatory diseases."
Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022.
VERU公司(纳斯达克代码:VERU)是一家专注于开发治疗新冠肺炎和其他病毒性疾病和ARDS相关疾病以及治疗乳腺癌和前列腺癌的新药的生物制药公司。该公司今天宣布,任命乔尔·巴滕为执行副总裁兼其美国传染病专营权的负责人,自2022年5月23日起生效。
Most recently Mr. Batten has been the Head of the Respiratory Syncytial Virus (RSV) Franchise at Sobi North America where he was responsible for the Synagis business with gross revenue of approximately $600M and a team of over 160 employees. Mr. Batten led sales and marketing for the RSV Franchise as well as strategy for market access, distribution and patient access services. Prior to Sobi, he spent approximately 20 years in a number of positions of increasing responsibility at AstraZeneca / MedImmune and Sanofi Aventis in various infectious disease franchises including commercial infrastructure build-out, product launch, sales management, marketing, public health sales, and government affairs.
最近,巴顿先生一直担任SOBI北美公司呼吸道合胞病毒(RSV)专营权的负责人,负责Synagis业务,毛收入约为6亿美元,拥有超过160名员工。巴顿先生负责RSV专营权的销售和营销,以及市场准入、分销和患者准入服务的战略。在加入SOBI之前,他在阿斯利康/医疗免疫公司和赛诺菲安万特担任了大约20年的多个职位,负责各种传染病特许经营,包括商业基础设施建设、产品推出、销售管理、市场营销、公共卫生销售和政府事务。
"Joel is an accomplished commercial leader with extensive knowledge in viral infectious disease product commercialization," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. "We are excited to have Joel join Veru at such a critical juncture in our Company's history as we build on the momentum of our positive Phase 3 sabizabulin for COVID-19 trial, our planned EUA submission, and the transition to delivering sabizabulin, if EUA is granted, to hospitalized COVID-19 patients at high risk for ARDS. Joel will be the head of our newly formed U.S. Infectious Disease Franchise and will be responsible for developing and leading all aspects of our U.S. go-to-market strategy for sabizabulin for COVID, if authorized, as well as planned future indications for other viral and ARDS-related and inflammatory diseases."
Veru公司董事长、总裁兼首席执行官、医学博士米切尔·施泰纳说:“乔尔是一位有成就的商业领袖,在病毒传染病产品商业化方面有丰富的知识。乔尔将成为我们新成立的美国传染病专营店的负责人,如果获得授权,我们将负责开发和领导我们治疗慢性阻塞性肺疾病的美国萨比布林的美国上市战略。我们很高兴乔尔能在我们公司历史的这样一个关键时刻加入VERU,我们巩固了我们新冠肺炎试验的第三阶段萨比布林的积极势头,我们计划中的欧洲药物治疗方案,以及如果获得批准,向住院的患有急性呼吸窘迫综合征的住院患者提供萨比布林的过渡。乔尔将成为我们新成立的美国传染病特许经营权的负责人,并将负责开发和领导我们治疗慢性阻塞性肺疾病的萨比布林的美国上市战略的所有方面,以及计划中的未来其他病毒和与急性呼吸窘迫综合征相关的炎症性疾病的适应症。“
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧